Cystic kidney
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
Short stature
|
0.100 |
GeneticVariation
|
phenotype |
CLINVAR |
|
|
|
Familial hematuria
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lama5 has been implicated in cancer cell survival, proliferation and invasion and is a known adhesion site for GBM cells.
|
30389143 |
2018 |
Secondary malignant neoplasm of liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
LAMA5 is required for the successful growth of hepatic metastases where it promotes branching angiogenesis and modulates Notch signalling.
|
31064120 |
2019 |
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
Alport Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
A modifier role of LAMA5 on the background of a hypomorphic Alport syndrome causing mutation is a possible explanation of our findings.
|
29764427 |
2018 |
Myasthenic Syndromes, Congenital
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A presynaptic congenital myasthenic syndrome attributed to a homozygous sequence variant in LAMA5.
|
29377152 |
2018 |
Polycythemia Vera
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adhesion was inhibited when PV RBCs were incubated with anti-Lutheran blood group/basal cell adhesion molecule (Lu/BCAM) or when HUVECs were treated with anti-laminin alpha(5) and to a lesser extent with anti-alpha(3) integrin.
|
17412890 |
2007 |
Multiple Myeloma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among them, the expression of ST3GAL6-AS1, LAMA5-AS1and RP11-175D17.3wereassociated with stage and risk status of MM.
|
29459023 |
2018 |
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis of human breast cancer cases revealed reduced survival in cases where α3 integrin and LAMA5 are both overexpressed.
|
24002891 |
2014 |
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis of human breast cancer cases revealed reduced survival in cases where α3 integrin and LAMA5 are both overexpressed.
|
24002891 |
2014 |
Colorectal Carcinoma
|
0.140 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
Malignant tumor of colon
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
Colorectal Neoplasms
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
Malignant neoplasm of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors.
|
14691145 |
2003 |
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.
|
27143691 |
2016 |
Secondary malignant neoplasm of liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
BCAM and LAMA5 were identified as molecular targets within both tumor cells and TME of KRAS-mutant hepatic metastasis from colorectal cancer, where they were specifically overexpressed.
|
27143691 |
2016 |
Colorectal Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
BCAM and LAMA5 were identified as molecular targets within both tumor cells and TME of KRAS-mutant hepatic metastasis from colorectal cancer, where they were specifically overexpressed.
|
27143691 |
2016 |